Shan Hama's questions to Zealand Pharma A/S (ZLDPF) leadership • Q1 2025
Question
Shan Hama from Jefferies asked how Zealand Pharma will define success for the upcoming Phase II dapiglutide trial and requested a preview of topics for the December Capital Markets Day.
Answer
President and CEO Adam Steensberg explained that success for dapiglutide involves confirming GLP-1-like weight loss and demonstrating differentiation by addressing inflammation. Chief Medical Officer David Kendall elaborated that success will be finding comorbidities where dapiglutide can outperform other incretins. For the Capital Markets Day, Steensberg said the theme will be obesity, market evolution, product fit, and the early-stage pipeline's future direction.